Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- Kenya on course to bring HIV under control — Unaidson November 20, 2019 at 1:15 am
Kenya is on course to meet some ambitious United Nations targets to control HIV by 2020. The Joint United Nations Programme on HIV/Aids targets that by 2020, 90 per cent of all people living with HIV ...
- Dance teacher pleads guilty to exposing teen boy to HIVon November 20, 2019 at 1:06 am
The Shelby County district attorney’s office said Tuesday that 30-year-old John Conner III avoided trial when he pleaded guilty to criminal exposure to HIV, statutory rape by an authority figure and ...
- Mapping the pathway to gut health in HIV and SIV infectionson November 19, 2019 at 7:57 pm
A UC Davis study found that the damaged gut lining (known as leaky gut) in monkeys infected with chronic simian immunodeficiency virus (SIV), an HIV-like virus, was rapidly repaired within five hours ...
- Memphis area dance teacher pleads guilty to exposing teen student to HIVon November 19, 2019 at 7:35 pm
Memphis area dance teacher pleads guilty to exposing teen student to HIV The defendant, John Conner III, also has two similar pending cases where he is charged with criminal exposure to HIV. Check out ...
- HPV infection and the genital cytokine milieu in women at high risk of HIV acquisitionon November 19, 2019 at 5:21 pm
Human papillomavirus (HPV) infection correlates with higher rates of HIV acquisition, but the underlying biological mechanisms are unclear. Here we study associations between HPV and HIV acquisition ...
- Dance teacher pleads guilty to rape, exposing teen to HIV chargeson November 19, 2019 at 12:32 pm
MEMPHIS, Tenn. (WREG) — A Tennessee dance teacher pleaded guilty to sex charges after authorities say he raped a student and exposed him to HIV. According to the Shelby County District Attorney ...
- CEO: Thrive Health's 'radical hospitality' drives high HIV suppression rateon November 19, 2019 at 6:38 am
Thrive Health Connection's new office at Prospect Avenue and 50th Street places the nonprofit in the heart of ZIP Code 64130, which has one of the area's largest populations of people living with ...
- Human Immunodeficiency Virus (HIV) Drugs Market Growth, Size, Statistics, Opportunities & Forecasts up to 2025on November 19, 2019 at 3:22 am
Nov 19, 2019 (AmericaNewsHour) -- The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. "Global Human Immunodeficiency Virus (HIV) Drugs Market ...
- HIV-positive dance coach pleads guilty to raping 16-year-old boyon November 19, 2019 at 12:08 am
An HIV-positive Tennessee man avoided trial this week after admitting to having unprotected sex with an underage dance student, who has since been diagnosed with the virus. Authorities said John ...
via Bing News